A multicenter, single-arm phase II trial of bevacizumab beyond initial progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in Advanced Colorectal Cancer

ABSTRACT: Interventions: bevacizumab plus mFOLFOX6 therapy (first-line treatment) bevacizumab plus FOLFIRI therapy (second-line treatment) Primary outcome(s): 2nd progression free survival (2nd PFS) Study Design: Single arm Non-randomized

DISEASE(S): Untreated And Unresectable Metastatic Colorectal Cancer

PROVIDER: 2622240 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR